Sector
PharmaceuticalsOpen
₹965Prev. Close
₹962.1Turnover(Lac.)
₹1,513.09Day's High
₹981Day's Low
₹940.152 Week's High
₹1,097.752 Week's Low
₹213.25Book Value
₹117.44Face Value
₹5Mkt Cap (₹ Cr.)
14,563.17P/E
0EPS
0Divi. Yield
05 Aug 2024
12:00 AM
Board Meeting
Agenda : Audited Result
5 Jun 2024
12:00 AM
AGM
Announcement Date: 05 Jun, 2024
WCK 6777 is the only once-a-day antibiotic in the global pipeline designated for outpatient parenteral antimicrobial therapy (OPAT).
| Y/e 31 Mar( In .Cr) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 |
|---|---|---|---|---|
Equity Capital | 77 | 72 | 72 | 55 |
Preference Capital | 0 | 0 | 0 | 0 |
Reserves | 1,719 | 1,681 | 2,140 | 1,551 |
Net Worth | 1,796 | 1,753 | 2,212 | 1,606 |
Minority Interest |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Revenue | 1,372 | 987 | 890.06 | 2,477.29 |
yoy growth (%) | 39 | 10.89 | -64.07 | 7.82 |
Raw materials | -476 | -416 | -313.29 | -975.36 |
As % of sales | 34.69 | 42.14 | 35.19 | 39.37 |
Employee costs | -261 | -293 | -325.46 | -506.44 |
| Y/e 31 Mar( In .Cr) | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Profit before tax | -184 | -481 | -483.68 | 103.92 |
Depreciation | -171 | -184 | -173.39 | -106.24 |
Tax paid | 44 | 231 | 158 | -35.26 |
Working capital | 197 | -66.03 | -165.93 | -147.06 |
Other operating items |
| Y/e 31 Mar | Mar-2022 | Mar-2021 | Mar-2020 | Mar-2018 |
|---|---|---|---|---|
Growth matrix (%) | ||||
Revenue growth | 39 | 10.89 | -64.07 | 7.82 |
Op profit growth | -260.86 | 3.65 | -141.23 | 122.91 |
EBIT growth | -131.67 | 6.63 | -196.34 | -4.86 |
Net profit growth | -123.6 | -356.57 | -436.61 | -49.92 |
| Particulars (Rupees in Crores.) | Mar-2024 | Mar-2023 | Mar-2022 | Mar-2021 | Mar-2020 |
|---|---|---|---|---|---|
Gross Sales | 2,798 | 2,651 | 3,230 | 2,708 | 2,843.99 |
Excise Duty | 0 | 0 | 0 | 0 | 0 |
Net Sales | 2,798 | 2,651 | 3,230 | 2,708 | 2,843.99 |
Other Operating Income | 0 | 0 | 0 | 0 | 0 |
Other Income | 83 | 122 | 20 | 1,476 | 184.17 |
Company Name | LTP (₹) | P/E (%) | Mkt.Cap (₹Cr.) | NP Qtr (₹Cr.) | Div.Yield (%) | Sales Qtr (₹.Cr) | Book Value (₹) |
|---|---|---|---|---|---|---|---|
Sun Pharmaceuticals Industries Ltd SUNPHARMA | 1,887.75 | 166.48 | 4,63,359.57 | 237.82 | 0.7 | 4,409.74 | 98.75 |
Divis Laboratories Ltd DIVISLAB | 5,942.15 | 95.69 | 1,58,942.68 | 430 | 0.5 | 2,063 | 507.93 |
Cipla Ltd CIPLA | 1,618.9 | 34.18 | 1,35,756.05 | 1,055.94 | 0.77 | 3,752.25 | 346.39 |
Torrent Pharmaceuticals Ltd TORNTPHARM | 3,443.25 | 80.13 | 1,20,438.86 | 469 | 0.79 | 2,394 | 201.77 |
Dr Reddys Laboratories Ltd DRREDDY | 6,583.1 | 27.01 | 1,11,289.4 | 1,417.2 | 0.6 | 5,823.9 | 1,458.55 |
Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.
Executive Chairman
H F Khorakiwala
Managing Director
Murtaza H Khorakiwala
Executive Director
Huzaifa H Khorakiwala
Independent Director
Tasneem Mehta
Independent Director
Vinesh Kumar Jairath
Non-Exec & Non-Independent Dir
Zahabiya Khorakiwala
Independent Director
Akhilesh Gupta
Independent Director
Amelia Fernandes
Company Sec. & Compli. Officer
Rashmi Mamtura
Independent Director
Ahmad Javed
Tel: -
Website: -
Email: -
Tel: -
Website: -
Email: -
Reports by Wockhardt Ltd
Summary
Wockhardt Limited is a global pharmaceutical and biotechnology organization, providing affordable, high-quality medicines for a healthier world. The Company is Indias leading research-based global healthcare enterprise in fields of Pharmaceuticals, Biotechnology and a chain of advanced Super Speciality Hospitals. It has 12 manufacturing locations and there are 3 locations where research and development activities are carried out.The Company has manufacturing and research facilities in India, USA & UK and a manufacturing facility in Ireland. It has a significant presence in USA, Europe and India, with 83% of its global revenues coming from international businesses. Wockhardt is the only company in the world where USFDA has given QIDP Status (Qualified lnfectious Diseases Programme) for 5 of Anti-bacterial discovery programmes - 2 of them are Gram Negative and 3 Gram Positive effective against untreatable Superbugs. Wockhardts entire anti-infective portfolio particularly addresses the specific bacterial organism where resistances are high and breakthrough antibiotics are needed.Wockhardt Ltd was incorporated on July 8, 1999. In the year 2000, the company launched the cardiac drug enalapril maleate in the US through their marketing joint venture with Sidmak Laboratories. Also, they set up a corporate training centre with modern and state-of-the-art facility under one roof at Aurangabad. In the year 2001, the company terminated their three-year old marketing alliance with Sidmak
Read More
What is the Wockhardt Ltd share price today?
The Wockhardt Ltd shares price on NATIONAL STOCK EXCHANGE (NSE) is ₹949.3 today.
What is the Market Cap of Wockhardt Ltd?
Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Wockhardt Ltd is ₹14563.17 Cr. as of 10 Oct ‘24
What is the PE and PB ratio of Wockhardt Ltd?
The PE and PB ratios of Wockhardt Ltd is 0 and 8.22 as of 10 Oct ‘24
What is the 52 Week High and Low of Wockhardt Ltd?
The 52-week high/low is the highest and lowest price at which a Wockhardt Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Wockhardt Ltd is ₹213.25 and ₹1097.7 as of 10 Oct ‘24
What is the CAGR of Wockhardt Ltd?
Wockhardt Ltd's CAGR for 5 Years at 34.39%, 3 Years at 28.91%, 1 Year at 322.53%, 6 Month at 62.37%, 3 Month at 13.06% and 1 Month at -4.82%.
What is the shareholding pattern of Wockhardt Ltd?
The shareholding pattern of Wockhardt Ltd is as follows:
Promoters - 51.99 %
Institutions - 10.39 %
Public - 37.61 %
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2024, IIFL Securities Ltd. All Rights Reserved
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
Invest wise with Expert advice
